SillaJen, Inc. (KOSDAQ:215600)
South Korea · Delayed Price · Currency is KRW 3,755.00
+5.00 (0.13%)
Apr 10, 2026, 3:30 PM KST
SillaJen Revenue
In the year 2025, SillaJen had annual revenue of 9.23B KRW with 134.94% growth. SillaJen had revenue of 2.91B in the quarter ending December 31, 2025, with 90.70% growth.
Revenue
9.23B
Revenue Growth
+134.94%
P/S Ratio
56.15
Revenue / Employee
161.85M
Employees
57
Market Cap
517.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.23B | 5.30B | 134.94% |
| Dec 31, 2024 | 3.93B | -12.90M | -0.33% |
| Dec 31, 2023 | 3.94B | -1.07B | -21.42% |
| Dec 31, 2022 | 5.01B | 4.76B | 1,870.95% |
| Dec 31, 2021 | 254.36M | -1.42B | -84.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Holdings | 2.45T |
| Medy-Tox | 247.29B |
| BINEX | 168.47B |
| GC Cell | 165.52B |
| MEDIPOST | 73.66B |
| Onconic Therapeutics | 53.39B |
| Anterogen.Co.,Ltd. | 7.54B |
| GI Innovation | 5.84B |